Last reviewed · How we verify
Optimizing Frontline Therapy for DLBCL in Older Adults: A GLOfitamab-based, Response-adapted, Window-stYle Study (GLORY)
The researchers are doing this study to find out if the study treatment is an effective treatment that causes few or mild side effects in people with diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL), or transformed lymphoma. The treatment being tested in this study is glofitamab, polatuzumab, and obinutuzumab in combination with standard treatment (the combination of rituximab, cyclophosphamide, doxorubicin, and prednisone, or R-miniCHP).
Details
| Lead sponsor | Memorial Sloan Kettering Cancer Center |
|---|---|
| Phase | Phase 2 |
| Status | RECRUITING |
| Enrolment | 42 |
| Start date | 2025-01-16 |
| Completion | 2028-01 |
Conditions
- Diffuse Large B Cell Lymphoma (DLBCL)
- High Grade B Cell Lymphoma
Interventions
- Glofitamab
- Polatuzumab
- Rituximab
- Cyclophosphamide
- Doxorubicin
- Obinutuzumab:
Primary outcomes
- evaluate the complete response rate (CRR) — 1 year
according to the 2014 Lugano Response Criteria
Countries
United States